Navigation Links
BELLUS Health reports results for first half of fiscal 2009
Date:8/11/2009

ng through borrowings, share issuances, receiving funds through collaborative research contracts, distribution agreements or product licensing agreements, and ultimately, from obtaining regulatory approval in various jurisdictions to market and sell its product candidates and ultimately achieving future profitable operations. The outcome of these matters is dependent on a number of factors outside of the Company's control. These factors raise significant doubt about the Company's ability to continue as a going concern. Management continues to actively pursue additional financing. The Company is currently involved in ongoing discussions with several parties to secure partnership agreement, collaboration agreement, licensing agreement and/or sale with respect to its businesses, product or product candidates. While the discussions could lead to the signing of binding agreements in the coming weeks or months, there can be no assurance whatsoever that any such transaction will be put in place in the near future or at all As a result, there is material uncertainty as to whether the Company will have the ability to continue as a going concern and thereby realize its assets and discharge its liabilities in the normal course of business.

The consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. These financial statements do not include any adjustments to the carrying value and classification of assets and liabilities and reported revenues and expenses that may be necessary should the Company not be successful in its efforts to obtain additional financing, to receive significant funds on signing collaborative research and development contracts, distribution agreements or by out licensing its products or making significant product sales. Such adj
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine news :

1. BELLUS Health Inc. Announces $12 Million Rights Offering To Common Shareholders
2. BELLUS Health reports results for first quarter of fiscal 2009
3. BELLUS announces Chief Financial Officer to depart effective May 22, 2009
4. BELLUS Health inc. announces completion of first tranche of financing
5. BELLUS Health reports results for the fourth quarter of 2008
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
7. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
8. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
9. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
10. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
11. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... Women who store fat on their waist in middle age ...when they get older, reveals a new study from the ...ublished in the scientific journal Neurology . ,...is at greater risk of dying prematurely due to a h...nior lecturer at the Sahlgrenska Academy. "If they...
(Date:11/23/2009)... Augusta, Ga. - The Medical College of Georgia is ...igm shift in the care of patients with sickle cell...cine and University of Florida are partners in the...ans across Georgia to serve as "medical homes" for...a pain crisis sends them to the hospital and seeki...
(Date:11/23/2009)... Life-Science Focused Stra... of Marketing and Communication Professionals , ...23, 2009 -- LaVoie Group, a life science-focused s...at it has received the 2009 MarCom Gold Award in t...nd judged by the Association of Marketing and Comm...
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire-FirstCall/--AnnTa...thisyearasapartnerforthe6thannualThanksandGivingca....JudeChildren,sResearchHospital.Thisyearmarkstheth...ivinginitiative,hasparticipatedinthecampaignwherew...livesbysupportingSt.Judewhileshoppingthisholidayse...
(Date:11/23/2009)..., KANSASCITY,Mo.,Nov.23/PRNewswire/--Christin...rgestprivatelyownedinsurancebrokerage.Hoehnewillse...nefitServices practiceinLockton,s Minneapolis offi...nh/20090415/CG99351LOGO ) ,, "Wearethrilledtoha...ocktonInternationalBenefitServices."Shebroadensour...
Breaking Medicine News(10 mins):Health News:Initiative could result in paradigm shift in the care of sickle cell patients 2Health News:Initiative could result in paradigm shift in the care of sickle cell patients 3Health News:Initiative could result in paradigm shift in the care of sickle cell patients 4Health News:Initiative could result in paradigm shift in the care of sickle cell patients 5Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 2Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 3Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2Health News:Lockton Benefit Group Expands International Benefit Team 2
... Sept. 5 U.S. citizens can donate,money to provid...cane,Gustav, which is the worst storm to hit the i...org ), "Donations will be used for basic supplies...velopment Foundation, (http://www.padf.org ) in Wa...
... Sept. 5 As the general election,campaign begins ...endent,Business ( http://www.nfib.com ) is looking...focus on the healthcare concerns of small,business...ll businesses as they further develop their health...
...udy finds sorafenib helps reverse disease resistan...pt. 5 (HealthDay News) -- The drug sorafenib may h... anti-hormonal drugs, Georgetown University Medic...nti-hormonal medicines, such as aromatase inhibito...
...on, DCWomen with hormone-receptor positive, metast...to help keep their cancer at bay, but when the tum...ment with chemotherapy becomes the only option. Bu...itize" the tumor, allowing anti-hormonal drugs to ...
... New York Fashion Week,s Annual Des... New York, New York (PRWEB) September 5, 2...ser Centers __title__ American Laser], the largest...on Week. STYLE360, from Sept. 7-10, serves as the...
...SALEM, N.C. Free drug samples provided to physici...costing uninsured patients more in the long run, a...rest University Baptist Medical Center and colleag...he months immediately before and after the closing...
Other Medicine News:Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2Health News:1 step back ... 2 steps forward 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3
(Date:11/23/2009)...ewswire/--AMDLASERSannouncedthisweekthatitcontinue...ingwithprestigiousindustry-leaderDr.LarryRosenthal...eexclusivesofttissuediodelaserusedduringallinterna...op2%ofdentists. ,, (Photo: http://www.newscom.c...greatpleasurethatIproudlyannounceourpartnership.So...
(Date:11/23/2009)...Newswire-FirstCall/--RaptorPharmaceuticalCorp.("Ra...resultsfromaPhase2bclinicaltrialofitsproprietaryde...npatientswithnephropathiccystinosis("cystinosis")....iego("UCSD")GeneralClinicalResearchCenter,evaluate...namicsofasingledoseofDRCysteamineinninecystinosisp...
(Date:11/23/2009)...v.23 /PRNewswire/-- LaerdalMedical,inalliancewit...secondvolumeofpre-programmedscenariosforusewithLae...sdesignedtointegratesimulationintotheAAP,sNeonatal...tmentofothercriticalmedicalconditionsintheneonatal...n/prnh/20091123/NY14903LOGO ) ,, (Logo: http://...
Breaking Medicine Technology:AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 2New Jersey Hospital to Pay 243 Million to Resolve Allegations of Medicare Fraud 61648 1New Jersey Hospital to Pay 243 Million to Resolve Allegations of Medicare Fraud 61648 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Delcath Systems Announces Completion of Public Offering 6385 1Delcath Systems Announces Completion of Public Offering 6385 2
.... 21 FASgen is pleased to report the,publication ...ield using,FAS89B, one of the Company,s proprietar...search into selective inhibition of fatty acid syn... in the area of metabolic,disease disorders, speci...er disease. The Company has a long-standing cooper...
..., Dec. 20 Novavax, Inc.,(Nasdaq: NVAX ) announce...Ia,human clinical trial of its non-adjuvanted pand...andidate., Penny Heaton, MD, Chief Medical Office...itial results from our Phase I/IIa study are,promi...ic influenza vaccine,through regulatory licensure....
Other Medicine Technology:FASgen Announces a New Discovery in Obesity Research 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4
...tient Comfort than chest tubes and Enhanced Ambula...cone drains with four channels along the sides wit...ist of a silicone hub, a silicone extension tubing.../4 fluted (hub outside skin) or full fluted (hub i...
Laparoscopic Introducer Set
Fanelli Laparoscopic Endobiliary Stent Set
Common Duct Exploration Set: With N-Circle® Nitinol Tipless Stone Extractor
Medicine Products: